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Dendritic cell homeostasis
Abstract
Dendritic cells (DCs) are a heterogeneous fraction of rare hematopoietic cells that coevolved with the
formation of the adaptive immune system. DCs efficiently process and present antigen, move from sites
of antigen uptake to sites of cellular interactions, and are critical in the initiation of immune responses as
well as in the maintenance of self-tolerance. DCs are distributed throughout the body and are enriched in
lymphoid organs and environmental contact sites. Steady-state DC half-lives account for days to up to a
few weeks, and they need to be replaced via proliferating hematopoietic progenitors, monocytes, or
tissue resident cells. In this review, we integrate recent knowledge on DC progenitors, cytokines, and
transcription factor usage to an emerging concept of in vivo DC homeostasis in steady-state and
inflammatory conditions. We furthermore highlight how knowledge of these maintenance mechanisms
might impact on understanding of DC malignancies as well as posttransplant immune reactions and their
respective therapies.
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Dendritic cells (DCs) are a heterogeneous
fraction of rare hematopoietic cells that
coevolved with the formation of the adap-
tive immune system. DCs efficiently pro-
cess and present antigen, move from
sites of antigen uptake to sites of cellular
interactions, and are critical in the initia-
tion of immune responses as well as in
the maintenance of self-tolerance. DCs
are distributed throughout the body and
are enriched in lymphoid organs and envi-
ronmental contact sites. Steady-state DC
half-lives account for days to up to a few
weeks, and they need to be replaced via
proliferating hematopoietic progenitors,
monocytes, or tissue resident cells. In
this review, we integrate recent knowl-
edge on DC progenitors, cytokines, and
transcription factor usage to an emerging
concept of in vivo DC homeostasis in
steady-state and inflammatory condi-
tions. We furthermore highlight how
knowledge of these maintenance mecha-
nisms might impact on understanding of
DC malignancies as well as posttrans-
plant immune reactions and their respec-
tive therapies. (Blood. 2009;113:3418-3427)
Introduction
Dendritic cells (DCs) are hematopoietic cells that belong to the
antigen-presenting cell (APC) family, which also includes B cells
and macrophages. Although Langerhans cells (LCs) in the skin
were described in 1868, the role of DCs as APCs was not
appreciated until 1973, when Steinman and Cohn first identified
DCs in mouse spleen as potent stimulators of the primary immune
response.1 Shortly thereafter, several groups reported the presence
of DCs in nonlymphoid tissues of rodents and humans and
demonstrated early evidence that these cells contribute to heart and
kidney transplantation rejection.2 However, the low number of DCs
in vivo, the paucity of markers that distinguish them from
monocytes/macrophages, and the problems in purifying these cells
made for slow progress. In the 1990s, the development of methods
to isolate and generate DCs from blood and bone marrow (BM) led
to explosive growth of the DC field.3-5 Studies in the last decade
have established the critical role of DCs in the maintenance of
immunologic integrity and their importance in the development
and potential treatment of human disease, leading in 2007 to the
attribution of the Albert Lasker Award for Basic Medical Research
to Dr Ralph Steinman (Rockefeller University, New York, NY) in
recognition of his discovery of DCs.
Heterogeneity, localization, and life cycle of
DC populations
DCs are a heterogeneous population of cells that can be divided
into 2 major populations: (1) nonlymphoid tissue migratory and
lymphoid tissue–resident DCs and (2) plasmacytoid DCs (pDCs,
also called natural interferon-producing cells). The term “classic”
or “conventional” DCs (cDCs) has recently been used to oppose
lymphoid organ–resident DCs to pDCs. Nonlymphoid organ DCs,
on the other hand, are mainly called tissue DCs. Although the term
cDC is helpful in some respect, it also might be confusing as
nonlymphoid tissue DCs are also different from pDCs, and primary
nonlymphoid tissue DCs can be found in lymph nodes (LNs) on
migration but are not cDCs. Thus, throughout this review, the term
DCs will refer to all non-pDCs whether they are present in
lymphoid or nonlymphoid tissues, and location will be appropri-
ately specified.
Migratory and resident DCs have 2 main functions: the
maintenance of self-tolerance and the induction of specific immune
responses against invading pathogens,1,6 whereas the main function
of pDCs is to secrete paramount amounts of interferon- in
response to viral infections and to prime T cells against viral
antigens.7 Figure 1 and Table S1 (available on the Blood website;
see the Supplemental Materials link at the top of the online article)
show different DC populations, their frequencies, locations, and
turnover in various lympoid and nonlymphoid tissues.
DCs in nonlymphoid tissues
Nonlymphoid tissue DCs can be distinguished between those
present in sterile tissues, such as the pancreas and the heart, DCs
present in filtering sites, such as the liver and the kidney, and DCs
present at environmental interfaces as lung, gut, and skin. Among
interface DCs, epidermal DCs, also called LCs, are the most
studied. LCs constitutively express major histocompatibility com-
plex (MHC) class II and high levels of the lectin langerin, forming
the intracytoplasmic birbeck granule. Human LCs express CD1a, a
MHC class I homolog that is often used to identify human LCs.
Recent data established that langerin expression is not specific for
LCs. In mice, langerin is expressed at low levels, on CD8 DCs in
lymphoid organs, and on a population of DCs present in the lung
and the dermis.8,9 These langerin interstitial DCs express low
levels of the integrin CD11b and coexpress E7 (CD103), a
ligand of the cell adhesion molecule E-cadherin expressed by most
epithelial cells. CD103 DCs negative for langerin have also been
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identified in the gut. In addition to CD103 DCs, tissues also
contain another major DC population that is characterized as MHC
class IICD11cCD11bhiCD103langerin. The exact contribu-
tion of each of these populations to tissue immunity is currently
being examined.
Tissue DCs sample antigens and migrate constantly through
afferent lymphatics to the T-cell areas of LN, a process that
increases manyfold in response to inflammatory signals.10 Al-
though DC efflux from tissues to the tissue-draining LN is difficult
to accurately quantify,11 it is clear that tissue-DC homeostasis
requires constant replacement with new cells. BM chimera studies
in mice established that kidney and heart DCs are replaced in 2 to
4 weeks after lethal irradiation and BM transplantation, whereas
DC repopulation in the vagina,12 airway epithelia,13 and the gut is
more rapid and occurs in 7 to 13 days (M. Bogunovic and M.M.,
unpublished data, January 2009). In the thoracic duct from
mesenteric lymphadenectomized rats, the first DCs were detected
at 24 hours and peaked at 3 days after labeling, suggesting that the
turnover time of gut DCs is very rapid.14
In contrast, epidermal LC life span differs fundamentally from
that of other DCs.15 Approximately 2% to 3% LCs are constantly
cycling, and LCs resist lethal dose of irradiation and remain of host
origin in BM chimeric animals more than 18 months after
transplantation.16 It is therefore possible that both local hematopoi-
etic precursor cells and differentiated LCs through self-renewal
could contribute to LC steady-state homeostasis, depending on
physiologic needs, as has been shown for skin stem cells.
Although not representative for steady-state turnover, it is
interesting that, in patients who received allogeneic hematopoietic
cell transplantation (allo-HCT), recipient LCs can be identified
unequivocally in the epidermis more than 1 year after allo-HCT.17
Donor LCs have also been shown to persist for years in a recipient
of a human limb graft,18 suggesting that human LCs as their murine
counterparts repopulate locally in steady state.
DCs in lymphoid tissues
Lymphoid tissue–resident DCs are the most studied DC popula-
tions in mice, but little information is available on their human
counterparts.
The spleen is populated via blood. In mice, splenic DCs
constitutively express MHC class II and the integrin CD11c. They
are further classified into 2 major subsets that include
CD4CD8CD11b DCs that localize mostly in the marginal
zone and CD8CD4CD11b DCs localized mostly in the T-cell
zone.19 CD4CD8CD11b DCs have also been identified and
are called double-negative DCs. CD8 DCs are specialized in
MHC class I presentation, whereas CD4 DC subset is specialized
in MHC class II presentation. CD8 DCs have also been shown to
cross-present cell-associated antigens, whereas CD4 DCs are
unable to do so.20 CD8 is not expressed on human DCs, but recent
data from 2 separate groups identified in human blood a DC subset
that resembles the mouse CD8 DCs (discussed in “Blood DCs”).
In vivo bromodeoxyuridine (BrdU) labeling studies in mice
revealed that 5% lymphoid organ DCs or their immediate progeni-
tors are actively cycling at any given time.21 Results from
parabiotic mice that share the same blood circulation for prolonged
periods of time showed that, 3 weeks after parabiosis, 30% spleen
DCs derive from parabiont partners. On separation, partner-derived
DCs are entirely replaced by endogenous-derived cells in 10 to
14 days. These data prove that, although DC progenitors proliferate
locally with small burst size, they do not self-renew and are
continuously replaced by blood-borne precursors.22-24
LN DCs are more heterogeneous as they include blood-derived
lymphoid tissue–resident CD8, CD4, and double-negative
spleen equivalent DCs, and migratory DCs entering via the afferent
lymphatics that vary according to the LN draining site.10 For
example, migratory epidermal LCs and dermal DCs are present in
skin-draining LNs but are absent from mesenteric LNs. Blood-
derived DCs or their local progenitors have similar turnover rates
as spleen DCs, whereas the life span of tissue-derived DC varies as
discussed in “DCs in nonlymphoid tissues.”
Mucosa-associated lymphoid tissues include lymphoid tissue in
the nasopharynx, Peyer patches and isolated lymphoid follicles in
the small intestine, and isolated follicles and the appendix in the
large intestines. These tissues are mostly populated by blood-
derived cells, and the phenotype and probably also turnover
resemble those of spleen DCs.25
Thymic DCs localize mostly in the medulla. The majority of
mouse thymic DCs are CD8 and are thought to be generated
locally from early thymocyte progenitors. A minority of DCs is
CD8 and is best characterized by the expression of signal
regulatory protein- and is thought to derive independently of
thymic progenitors.26 Thymic DCs play a major role in negative
selection of T cells.27 A recent study suggests that circulating DCs
can enter the thymus and are involved in both establishment of
central tolerance and the induction of antigen specific T-regulatory
cells28 (Li Wu, XIIth International DC Meeting, Kobe, Japan,
2008). Thymic CD8 and CD8 DCs incorporate BrdU in a
biphasic pattern with a rapid uptake in the first 3 days followed by a
lag period giving rise to 80% labeled DCs in 10 days.29 Data from
the parabiotic model have also identified 2 separate homeostatic
patterns among thymic DCs.30 One DC population fails to equili-
brate among parabionts, reaching similarly to thymocytes, less than
10% chimerism after 5 weeks of parabiosis, suggesting that this
Figure 1. Mouse DC populations, location, and turnover in steady state. DCs are
distributed throughout the body. The major DC subpopulations at hematopoietic sites,
environmental contact sites, filtering sites, and immune priming sites are depicted.
Frequencies are given as percentage of total nucleated hematopoietic cells. Time to
approximately 50% renewal in steady state is given in days (d). *Skin-draining LN;
**epidermis; present, but exact numbers not known;1, present in inflammation.
Professional illustration by Debra T. Dartez.
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DC population derives from an intrathymic progenitor.26 In con-
trast, a second thymic DC population rapidly exchanged among
parabionts, reaching 50% chimerism in 5 weeks probably represent-
ing the blood-borne thymic DCs discussed in this section.
Plasmacytoid DCs in lymphoid and nonlymphoid tissues
Similarly to DCs, pDCs constitutively express MHC class II
molecules and lack most lineage markers. Murine pDCs lack
CD11b and express low levels of the integrin CD11c and the
lineage markers CD45RA/B220 and ly6C /GR-1, and express
PDCA1 and siglec-H, a member of the sialic acid binding Ig-like
lectin (Siglec) family and recently identified as a specific surface
marker for mouse pDCs.7,19,31 Human pDCs express very low to no
level of CD11c, they express CD4 and CD45RA antigens, the
c-type lectin receptor BDCA2, and the molecule BDCA4, a
neuronal receptor often used to isolate pDCs, and high levels of the
interleukin-3 (IL-3) receptor (CD123). pDCs circulate in blood and
are found in steady-state BM, spleen, thymus, LN, and the liver.
Human and mice pDCs enter the LN through the high endothelial
venule and accumulate in the paracortical T cell–rich areas.32 In
contrast to DCs, pDCs do not efficiently migrate to peripheral
tissue in the steady state with the exception of the liver. pDC
proliferation rate in lymphoid organs is very low, and less than
0.3% pDCs are in cell cycle. On continuous BrdU labeling over
14 days in vivo, 90% of pDCs were positive,33 and on separation
of parabiotic mice, donor-derived pDCs are replaced in 3 days.22
Thus, the lifespan of differentiated pDCs in the spleen and LN is
very short and continuous replacement via blood is essential.
Blood DCs
Blood DCs have been mostly studied in humans where both DCs
and pDCs can be found. In patients who received allo-HCT, blood
DCs and pDCs are replaced by donor-derived cells in less than a
week after transplantation.17 Recent data from 2 separate groups
identified a potential counterpart of the mouse lymphoid organ
CD8 DCs in human blood,34,35 providing a unique opportunity to
examine whether human DCs share the functional specialization of
the CD8 DC system. Mouse blood DCs are less well character-
ized. The majority of circulating MHC class IICD11c are pDCs,
but low numbers of MHC class IICD11c DCs and MHC class
IICD11c DC progenitors shown to give rise to CD8 and
CD8 DCs in lymphoid organs can also be detected.36
Cytokines in DC development
The discovery that granulocyte-macrophage colony-stimulating
factor (GM-CSF) is a key cytokine for the differentiation of mouse
and human hematopoietic progenitors3,4 and human monocytes5
into DCs in vitro marked the acceleration of DC research. It then
came as a surprise that DCs develop normally in mice that lack
GM-CSF or its receptor.37 Similarly, mice injected with GM-CSF
or transgenic mice overexpressing GM-CSF have only moderate
changes in DC numbers37,38 (Table S2 summarizes cytokine effects
on in vivo DC homeostasis). It is only when mice are injected with
GM-CSF–expressing adenovirus or with GM-CSF with engineered
long half-life that massive expansion of CD8 DCs secreting
“inflammatory” cytokines tumor necrosis factor- (TNF-), IL-6,
and inducible nitric oxide was observed. GM-CSF is produced by
tissue stromal cells, and by activated T cells and NK cells.
Although GM-CSF is not detectable in steady-state serum, it
increases during inflammation.39 Thus, although GM-CSF is dis-
pensable for steady-state DC development, it can play a role in DC
differentiation in inflammatory situations. Consistent with these
data, injection of GM-CSF is used in clinical studies to attract or
generate DCs at disease sites.40 In vivo GM-CSF–driven DC
differentiation may resemble the in vitro GM-CSF cultures involv-
ing GM-CSFR-expressing monocytes.
In contrast, genetic deletion of Fms-like tyrosine kinase 3 ligand
(Flt3L) or treatment with Flt3 tyrosine kinase inhibitors in mice
leads to 10-fold reduction of pDCs and DCs in lymphoid or-
gans,41,42 whereas LCs are largely unaffected (M.M. and M.G.M.,
unpublished data, January 2009). Injection or conditional expres-
sion of Flt3L leads to massive expansion of both pDCs and DCs in
all lymphoid and nonlymphoid organs, including the large and
small intestine and the liver, with up to 30% of mouse spleen cells
expressing CD11c.38,43,44 Consistently, Flt3L as a single cytokine
can drive differentiation of mouse BM progenitors into all DC
subtypes in vitro, including pDC differentiation, which cannot be
generated in GM-CSF–supplemented cultures.45,46 Similarly, Flt3L
supports in vitro development of pDCs and DCs from human
hematopoietic progenitors,47-49 and Flt3L injection in humans leads
to massive expansion of blood pDCs and DCs.50 Thus, in contrast
to GM-CSF, Flt3L is both sufficient and essential for the develop-
ment of blood and lymphoid organ DCs and pDCs. Flt3L exists in
both a soluble and membrane-bound form and is expressed by
multiple tissue stroma cells and by activated T cells.51 Bioactive
levels of Flt3L are measurable in serum in steady state and increase
on inflammation and hematopoietic stress, such as irradiation-
induced cytopenia. In addition, mice that lack Flt3 receptor, mice
treated with Flt3 tyrosine kinase inhibitors, and mice with targeted
DC depletion show 10- to 20-fold increased levels of serum
Flt3L42,52 (M. Schmid and M.G.M., unpublished data, January
2009). Together, these data show that Flt3L plays a key and
nonredundant role in DC development in BM and peripheral
lymphoid organs, and Flt3L levels are adjusted via a regulatory
loop tailored to ensure sufficient DC production in steady state
and on demand.
CSF-1 (M-CSF) is a key cytokine for macrophage develop-
ment. Mice that lack CSF-1 or its receptor (CSF-1R) lack several
macrophage populations and develop osteopetrosis because of the
absence of osteoclasts.53,54 Although initially thought to be dispens-
able for DC development,55 data from our laboratory established
that CSF-1R is required for LC development.56 CSF-1 reporter
mice revealed that Csf-1r mRNA is expressed by most lymphoid
organ DCs, but the exact correlation of Csf-1r mRNA levels and the
protein expression in these mice remains unclear.57 CSF-1 can also
enhance DC numbers in cultures, and injection of CSF-1 increases
both lymphoid organ pDCs and DCs in mice.58,59 CSF-1 is
expressed by endothelia, stroma cells, osteoblasts, and macro-
phages, and, as Flt3L, is detectable in steady-state serum and
increases on inflammation39 (M. Schmid and M.G.M., unpublished
data, January 2009). Consistently, we found that monocytes
repopulate LCs in inflamed skin in a CSF-1R–dependent manner.56
CSF-1R might also be involved in other nonlymphoid tissue DC
development, but its exact role in DC differentiation remains to
be examined.
In addition to CSF-1, transforming growth factor-1 (TGF-1)
is a nonredundant cytokine for LC development in vivo in mice,60
and similarly supports LC development in vitro from human
hematopoietic progenitors.61 In the skin, keratinocytes are a large
source of TGF-1, and it has been assumed that exogenous
TGF-1 was critical for LC development. Recent data, however,
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have challenged this view as mice in which absence of TGF-1
secretion is restricted to LCs cannot develop epidermal LCs,62
suggesting that LCs might control their development in an auto-
crine fashion.
Whereas Flt3L, GM-CSF, CSF-1, and TGF-1 are major
known cytokines for in vivo DC development, other cytokines,
such as IL-4, TNF-, LT, and G-CSF, probably have more subtle
effects within steady-state and inflammatory DC homeostasis. The
complex interaction of cytokines required for optimal DC differen-
tiation should be addressed by investigating combined cytokine
effects in vivo but also by in vivo imaging via labeling of
cytokine-producing cells and cytokine receptor–expressing DC
progenitors.
Transcription factors in DC development
Environmental stimuli, as cytokines, need to be translated on the
subcellular level. The use of knockout mouse models revealed key
roles of several transcription factors in DC development, some of
which are required for global DC development, whereas others are
restricted to specific DC subsets. We here discuss those that are
currently understood in the context of signaling networks and
provide a more complete list in Table 1.
Transcription factors affecting all DC-type development
Hematopoietic deletion of STAT3, a transcription factor in down-
stream Flt3 signaling, leads to reduced lymphoid organ DC
development,63 whereas overexpression and activation of STAT3 in
flt3-negative hematopoietic progenitors rescued both pDC and DC
differentiation potential.64 Consistently, deletion of the transcrip-
tional repressor Gfi-1, which is involved in regulating STAT3
activation, leads, besides many other hematopoietic developmental
deficiencies, to the reduction of all lymphoid tissue DCs, whereas
LC numbers were increased.65 Importantly, although STAT3 defi-
ciency blocks Flt3L-mediated pDC and DC development, it does
not block GM-CSF–mediated DC development.63 GM-CSF pro-
motes DC development via STAT5 that in turn via direct suppres-
sion of Irf-8 (also called ICSBP, described in “Transcription factors
affecting specific DC populations”) inhibits pDC development.
GM-CSF also leads to STAT3 activation and to Irf-4 expression, a
transcription factor important in DC development66 (discussed in
“Transcription factors affecting specific DC populations”). Indeed,
pDCs develop in vitro in GM-CSF–stimulated cultures in the
absence of STAT5, possibly mediated by STAT3 activation. In
addition, GM-CSF–stimulated Stat5-deficient progenitors produce
fewer DCs, and hematopoietic Stat5-deficient mice have a slight
reduction of lymphoid organ DCs, paralleling the findings in
GM-CSF–deficient animals37,66 (D. Kingston and M.G.M., unpub-
lished data, January 2009). Steady-state lymphoid organ pDC
maintenance, however, seems not to be suppressed by GM-CSF
downstream STAT5 activation, as GM-CSF–deficient mice do not
show increased pDC numbers (D. Kingston and M.G.M., unpub-
lished data, January 2009).
Transcription factors affecting specific DC populations
The NF-B/Rel family member RelB is expressed in lymphoid
organs. RelB/ mice have an altered thymic organ structure and
develop myeloid hyperplasia and multiorgan inflammation.67 RelB
is expressed in DCs, with relatively higher amounts in CD8
DCs, and RelB deficiency leads to massive reduction of CD8
DCs.68 In line with these findings, similar alterations of the
lymphoid organ cDC compartment are observed in mice deficient
in TRAF6, a TNF receptor–associated factor family protein, acting
upstream of the NF-B cascade.69
The ETS family of DNA binding proteins member PU.1 is a
transcription factor expressed in hematopoietic cells, and its
deletion causes embryonic or neonatal death. Mice reconstituted
with Pu.1-deficient hematopoietic cells, in addition to other
hematopoietic defects, have strong reduction in CD8 and
CD8 cDCs, and GM-CSF cannot induce DC differentiation from
PU-1–deficient progenitors in vitro.70,71 PU-1 is also expressed on
Flt3 signaling and enforced Pu.1 expression in Flt3megakaryocyte-
erythrocyte lineage committed hematopoietic progenitors is suffi-
cient to permit the development of both pDCs and DCs.64 In
human CD34 progenitor cells, knockdown of Pu.1 inhibits pDC
development, as did the knockdown of another ETS transcription
factor, Spi-B.72
The interferon regulatory factors (IRFs) 2, 4, and 8 were
described as key transcription factors involved in DC subset
Table 1. Transcription factor effects on in vivo DC homeostasis
Transcription
factor
Bone marrow
DC progenitor
Spleen
pDC
Spleen DC
CD8a/
Langerhans
cells References
Stat3/ NA NA 0.1/0.1 NA 63
Gfi-1/ 0.2 0.5 0.5/0.5 2 65
Stat5/ NA 0.4 0.4/0.3 NA 66
Ikaros/ NA NA Absent/0.15 NA 122
Ikaros DN/ NA NA Absent NA 122
Ikaros IkL/L NA  0.1 0.8/1.1 NA 123
Xbp-1/ NA 0.3 0.6 NA 124
RelB/ NA NA Absent/1 1 68
Pu.1/ NA NA  0.1/1 NA 70,71
Irf-2/ NA NA 0.25/1 0.7 73
Irf-4/ NA 0.5-1 0.3/1 NA 74,75
Irf-8/ 1 0.1 1/0.1 0.5 76,77
Id2/ NA 1.5 1/ 01 Absent 78
Runx3/ NA NA 0.8/2 Absent 81
E2-2/ NA  0.1 1/1 NA 79
Batf3/ NA 1 1/ 0.1 NA 80
Values are given as approximate fold of wild type.
NA indicates not available.
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diversification. Irf-2–deficient mice display reduced CD8 DCs
and slightly reduced LCs,73 Irf-4–deficient mice have reduced
CD8 DCs and slightly reduced pDCs,74,75 and Irf-8 knockout
mice have reduced CD8 DCs, pDCs, and LCs.76,77 In vitro DC
differentiation on GM-CSF stimulation depends preferentially on
IRF-4, whereas DC differentiation on Flt3L preferentially depends
on IRF-8,75 in line with the differential use of STAT5 and STAT3 in
GM-CSF and Flt3L-driven DC development.66
Basic helix-loop-helix transcription factors (E12, E47, HEB,
E2-2) act as transcriptional activators and are inhibited by counter-
acting HLH Id (inhibitors of DNA binding) proteins. It has been
demonstrated that Id2 is induced during GM-CSF–driven DC
development in vitro, and Id2-deficient mice have moderately
increased pDCs, severely reduced CD8 DCs, and lack LCs.78
Interestingly, Tgf-1 delivers the upstream signal for Id2; thus, LC
deficiency in TGF-1 knockout mice can be directly linked to the
LC deficiency observed in Id2-deficient mice.78 In addition, very
recently, hematopoietic deletion of basic helix-loop-helix E2-2 was
shown to block pDC development at an immature stage in mice,
and similar, haplo-insufficiency of E2-2 in humans leads to a
functional pDC defect (Pitt-Hopkins syndrome).79 Ectopic expres-
sion of Id2 and Id3 in human CD34 hematopoietic progenitor
cells causes inhibition of pDC but not DC development in vitro,48
whereas ectopic expression of the transcriptional activating HLH
gene E2A (encoding E12, E47) stimulates pDC development
(similar as Spi-B discussed above in this section).72
Batf3, also known as Jun dimerization protein p21SNFT, has
recently been discovered using global gene expression analysis as a
molecule highly expressed in DCs, with low to absent expression in
other immune cells and nonimmune tissues. Strikingly, Batf3/
mice lack specifically CD8 DCs in the spleen and LN. Nonlym-
phoid tissue DCs have not been thoroughly studied, with the
exception of the skin, where specific defect of CD103 but not
CD103 DCs, has been reported. Importantly, Batf3/ mice are
unable to mount antitumor and antiviral immune response establish-
ing a key role for Batf3 cells in the priming of CD8 T cells.80 It is
critical to explore in details the specific DC defects in nonlymphoid
tissues of Batf3/ mice because it is probable that additional
defects in the nonlymphoid tissue compartment may participate in
the immune phenotype.
Runx3, a member of the runt domain family of transcription
factors, mediates TGF- responses. Lack of Runx3 in mature DCs
results in loss of TGF-–mediated inhibition of maturation,
therefore leading to DC activation and inflammation. Importantly,
lack of appropriate TGF-–induced Runx3 signaling also leads to a
defect in LC development.78,81
Differentiation of DCs from hematopoietic
progenitor cells
Hematopoiesis is hierarchically structured. A small fraction of
self-renewing hematopoietic stem cells (HSCs) in BM gives rise to
non–self-renewing multipotent progenitors, which will give rise to
proliferating progenitors with gradually restricted developmental
options that finally differentiate into mature, mostly nondividing
cells. Early committed progenitors as clonal common lymphoid
progenitors and clonal common myeloid progenitors have been
identified in mice and humans.82 In addition to these committed
progenitors, more recent studies reveal overlapping and alternative
graded stages of early lineage commitment.83
Early hematopoietic development
Early lymphoid and myeloid committed progenitors maintain
developmental options for all DCs and pDCs in mice and hu-
mans.23,24,49,84,85 It is important to note that adoptive transfer of
myeloid and lymphoid progenitors from BM into irradiated ani-
mals revealed a similar bias toward CD8 DC generation as
observed in initial studies investigating adoptive transfer of early
thymocyte progenitors. Thus, it is now accepted that both myeloid
and lymphoid progenitors give rise to lymphoid organ CD8 and
CD8 DCs and the term “lymphoid” and “myeloid” DCs should
not be used any more in this context.23,24,84,86 DC generation from
early committed progenitors is transient and lasts for 2 to 4 weeks,
in accordance with lack of progenitor and DC self-renewal
potential. Subsequent studies revealed that maintenance of DC
developmental options by hematopoietic progenitors is linked to
Flt3 expression and to their ability to respond to Flt3L.43,87,88
Consistent with these data, enforced flt3 expression in early
progenitor cells opens access to a DC differentiation program that
can be used if no competing signals occur.64
Restriction to DC lineages
Given the fact that DC developmental options are maintained in
Flt3 early progenitors, the subsequent question was to determine
whether DC-committed precursors exist in the BM. Several
candidates have been recently identified that we here divide into
3 groups based on their proliferation potential (Table 2).
The first group comprises “early DC progenitors” present in
the BM. These progenitors have high proliferative capacity and
express CD117 (c-kit, the receptor for stem cell factor) but no
mature lineage marker. In clonal in vitro assays and on in vivo
transfer, they generate offspring cells severalfold the progenitor
input numbers. This group includes “macrophage and DC
progenitors” (MDPs)89 and “MDP,”90 which give rise exclu-
sively to monocytes, macrophages, and DCs, and “common DC
progenitors”58 and “pro-DCs,”91 which give rise exclusively to
pDCs and DCs.
The second group consists of further differentiated “late DC
progenitors” that are CD117 negative and express CD11c but not
MHC class II surface molecules and have low proliferative
capacity. In this group, clonal in vitro assays were not feasible with
current methods, and on transfer in irradiation conditioned hosts,
the recovery of progeny cells in the spleen is severalfold lower than
input numbers. This group includes BM CD11c MHC class
IIB220 cells, which generate exclusively pDCs and DCs,
CD11c MHC class IIB220 cells, which give rise exclusively to
DCs,92 “preimmunocytes,”93 which give rise to pDCs, DCs, and
macrophages, and peripheral blood “DC precursors,”36 which
generate spleen pDCs and DCs, and finally spleen “pre-cDCs,”94
which generate spleen DCs, but no pDCs.
The third group consists of nonproliferating Gr-1hi monocytes
with immediate DC precursor potential. DC differentiation in this
group has been described mostly at inflamed sites.12,56,94-97
It will now be important to clarify whether different early and
late progenitor populations are strictly distinct and multiple path-
ways to DC development exist, or whether, as most probably the
case, some are overlapping. In particular, it will be critical to
evaluate the intuitive evolutionary macrophage-DC linkage and to
delineate the mechanisms regulating the differentiation and branch-
ing points of monocyte, macrophage, DC, and pDC potential.
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Finally, and most importantly, the relative contribution of progeni-
tors to the DCs compartments in the steady state and during
inflammation needs to be determined.
The LC exception
In contrast to most DC populations, LCs are maintained locally
independently of circulating precursors in the steady state.16 This
could be via true self-renewal and/or via specialized local LC
precursor cells. The bulge region of the hair follicle serves as a
niche for keratinocytes, melanocytes, and mast-cell progenitors,
and there is evidence suggesting that, after epidermal injuries,
LCs can be repopulated from the follicles alone.98 Condi-
tional depletion of LCs and careful monitoring of their repopula-
tion should help to resolve these issues. In contrast, in inflamed
settings, LCs are replaced by circulating Gr-1hi monocytes in a
M-CSFR–dependent manner.56
A DC homeostasis integrated view
An integrated view on DC homeostasis is starting to emerge from
the data discussed in previous sections (Figure 2). All current data
indicate that homeostasis of short-lived lymphoid and nonlym-
phoid tissue DCs with the exception of the LCs relies on
continuous input from blood-borne cells.22,23,84,90,99
In steady-state spleen, and probably also in LN and mucosa-
associated lymphoid tissue, DCs enter as progenitor cells (MHC
class IICD11c) with limited proliferation potential and differen-
tiate into all DC subtypes.94 If local, lymphoid-organ Flt3L and
LT cause a 2- to 4-fold division of homed DC progenitors and
immature DCs, this local mechanism accounts for a substantial
expansion of entering cells and thus contributes importantly to
respective DC numbers.21,22,90,94 Whether entering progenitors also
harbor pDC differentiation potential remains to be determined.58
Indeed, pDCs are present in the BM and in the blood, suggesting
that pDC and DC developmental pathways may segregate earlier
and that relevant amounts of pDCs may be recruited separately.
In contrast to spleen and LN, a majority of thymic DCs differen-
tiate in situ from early thymic progenitors, and only a small
fraction of DCs or their immediate progenitors are recruited from
blood. Steady-state lymphoid organ DC homeostasis is primarily
driven by Flt3L in BM, blood, and in lymphoid organs them-
selves, and corresponds to Flt3 expression on proliferative DC
progenitors.41,43,58,63,87,89-91
The cellular correlates and the cytokines that maintain constant
homeostatic steady-state replacement of DCs in nonlymphoid
tissue that continuously travel to draining LNs is less clear. Both
DC progenitors and monocytes could contribute to this process.
Monocytes infiltrate nonlymphoid tissues in steady state and
they express Gm-csf and M-csfr, but little or no Flt3 mRNA43
(D. Kingston and M.G.M., unpublished data, January 2009), and it
is possible by analogy to in vitro findings that they require minute
amounts of tissue GM-CSF and/or M-CSF to differentiate into
DCs. In contrast to most DCs, LCs repopulate locally in the steady
Table 2. DC progenitor populations
Group/precursor
population name
Site of
isolation
Ex vivo sorting
immunophenotype
Frequency,
percentage
Differentiation
potential
in vitro
Clonal
potential
in vitro
Differentiation
potential
in vivo Conditions
Peak day of
progeny and
fold expansion
of input in
spleen References
Early DC progenitors (c-Kit, high proliferation potential)
MDPs
(macrophage and
DC progenitor)
BM LinCD117CX3
CR1CD11b
0.5 DC, Mac DC, Mac S, peritoneum:
Mo, DC, Mac
U, RT,
IF peritoneum
Day 7, 10 (RT) 89
MDPD
(macrophage and
DC progenitor)
BM LinCD117/
CD115
0.2 NA NA S:DC, Mac RT NA 90
CDPs (common
DC progenitors)
BM LinCD117intCD135
CD115 CD127
0.1 pDC, DC pDC, DC S, LN: pDC, DC U, RT Day 10, 7-8
(RT)
58
Pro-DCs BM LinCD117intCD135
CD16/32lo
NA pDC, DC pDC, DC S: pDC, DC U Day 8?, 0.05* 91
Late DC progenitors (c-Kit, low proliferation potential)
DC progenitors
B220
BM CD11cMHC class II
B220
0.3 pDC, DC NA S: pDC, DC RT Day 7?, 0.01
(RT)
92
DC progenitors
B220
BM CD11cMHC class II
B220
0.2 DC NA S: DC RT Day 7?, 0.03
(RT)
92
Preimmunocyte BM CD11cCD31Ly6C 0.5-1 pDC, DC, Mac NA NA NA NA 93
DC precursors Blood CD11cMHC class II 5 NA NA S: pDC, DC RT Day 14, 1 36†
Pre-cDCs Spleen CD11cintCD45RAlo
CD43intSIRP-aint
0.05 DC NA S: DC U Day 5, 0.02* 94
Monocytes (no proliferation potential)
Monocytes BM Ly6Chi (Gr-1hi) NA NA DC IF spleen Day 2 94
Monocytes Blood Gr-1hi NA NA LC IF skin 56
Monocytes BM Gr-1hi inflammatory NA NA DC IF intestine lung 97
Monocytes BM Gr-1hi and Gr-1 NA NA DC IF lung 96
Monocytes Blood Gr-1hi NA NA DC IF vagina 12
Data acquired in cellular transfer models.
U indicates unconditioned animals (ie, “steady-state” differentiation upon transfer in nonirradiated and noninflamed animals); RT, irradiation before transfer; IF, induction of
inflammation before or after transfer; S, spleen; LC, Langerhans cell; and NA, not available.
*Expansion in nonirradiated animals cannot be compared with expansion in irradiated animals.
†Population contained DX5 NK cells; purification of restricted blood DC precursors remains to be established.
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state, either through self-renewal or through a local hematopoietic
precursor that takes residence in the skin.
The development of DCs in inflamed nonlymphoid tissues has
been more thoroughly studied. In this setting, monocytes differenti-
ate into DCs and several cytokines, including GM-CSF, TNF-,
and IL-4, may play a role in this process.12,56,94-97 As Flt3L is
produced by activated T cells and Flt3L levels increase on systemic
infection, Flt3L may also contribute to inflammatory nonlymphoid
tissue monocyte to DC development by increasing monocyte
numbers in peripheral blood.43 Furthermore, HSCs, known to
continuously circulate in small numbers in steady-state blood,100
were identified in nonlymphoid tissues and in circulating lymph
and might give rise to additional DCs at inflamed sites in
emergency hematopoiesis,101 a process where early progenitor cell
expressed Toll-like receptor signaling might enhance DC differen-
tiation, short-cutting usual maturation steps.102
In contrast to DCs, pDCs locate in lymphoid tissues, BM, and liver,
but are rarely found in other tissues in the steady state, whereas they are
recruited in most tissue on tissue injury.7 The exact mechanisms that
control pDC trafficking remain to be identified.
DCs in hematologic disease
DC neoplasms
The 3 main hematopoietic DC neoplasms include Langerhans cell
histiocytosis, interdigitating DC sarcoma, and pDC leukemia/
hematodermic neoplasm. Because DC neoplasms are beyond the
scope of this review, we will only discuss a few aspects of these
diseases in the context of DC development and homeostasis.
First, the low prevalence of DC neoplasms has been attributed to DC
capacity to initiate antitumor immunity and used as an argument for
tumor immunosurveillance. An alternative hypothesis is that the short
DC half-life of mature DCs reduces the risk for acquiring sufficient
transforming genetic mutations. Indeed, the most frequent DC neoplasm
is Langerhans cell histiocytosis, a neoplasia derived from long-term
locally repopulating LCs. This hypothesis would be consistent with
recent understanding of the origin of cancer initiating cells or cancer
stem cells from somatic tissue stem cells.103
Second, it was shown that approximately one-third of acute
myeloid leukemias carry Flt3 gene mutations (internal tandem
duplications and kinase domain mutations), leading to constitutive
activation of Flt3 signaling.104 Given the relevance of Flt3 signal-
ing for DC homeostasis, it is intriguing that these mutations have
not been associated with or lead to DC neoplasias. This might be
because, although Flt3 signaling is required for DC homeostasis, it
also plays a role in early development of most hematopoietic
lineages. More importantly, downstream signaling pathways of
mutated, constitutively active Flt3 probably differ from wild-type
stimulated Flt3. In contrast to wild-type Flt3 signaling, constitu-
tively active signaling of Flt3-internal tandem mutations represses
PU.1 and c/EBP and activates STAT5 in a suppressors of cytokine
signaling (SOCS)–resistant fashion, probably a result of unphysio-
logic subcellular compartmentalization of the mutated protein.105
Third, early pDC leukemia/lymphoma (pDCL, CD4CD56
hematodermic neoplasm) was recently classified in the 2005 World
Health Organization/European Organization for Research and
Treatment of Cancer classification of cutaneous lymphomas as a
separate entity. pDCL cells coexpress pDC surface antigens and
transcription factors such as IRF-8 and PU.1, produce interferon-
on viral stimulation, and can mature into DCs that efficiently prime
T cells, and typically locate in organs that are infiltrated by pDCs
on inflammation.106,107 Interestingly, although no activating Flt3
mutations and only 13q12 deletions leading to allelic loss of Flt3
were detected, expression of surface Flt3 was found to be elevated
in pDCL.108 The biologic relevance of this, however, still needs to
be determined.
DCs in allo-HCT
The immunologic activity of donor T cells in allo-HCT grafts is a
critical factor in eradicating residual recipient hematopoiesis and
Figure 2. DC migration and homeostasis. HSCs produce DC progenitors, pDCs,
and DCs in the BM. Flt3 ligand is a nonredundant cytokine for BM DC differentiation,
although the exact role of GM-CSF and M-CSFR ligands remains to be determined.
BM-derived circulating blood cells maintain, with the exception of epidermal LCs, all
known steady-state DC homeostasis in lymphoid and nonlymphoid tissues. We
hypothesize that progenitor cells with limited proliferation potential on Flt3 ligand and
LT stimulation enter the LNs through high endothelial venules to maintain the
majority of LN DCs in steady state. It is also possible that nonproliferating blood DCs
follow the same route. In addition, nonlymphoid tissue DCs continuously enter the
LNs through afferent lymphatics, but these represent only a minority of steady-state
LN DCs. The specific contribution of proliferating DC progenitors, blood DCs, and
monocytes to nonlymphoid tissue DCs in the steady state and the relative involve-
ment of cytokines as Flt3 ligand, GM-CSF, and M-CSFR ligands remain to be to be
addressed. In contrast to most DCs, LCs repopulate locally in the steady state either
through self-renewal or through a local hematopoietic precursor that takes residence
in the skin. In inflamed skin, monocytes repopulate the LC pool via a TGF- and
monocyte colony-stimulating factor receptor–dependent pathway. In the steady state,
pDCs are recruited to the LN and other lymphoid organs directly from the blood and,
with the exception of the liver, enter most nonlymphoid tissues only on inflammation.
Whether lymphoid organ pDCs also derive from DC precursors that enter the organs
remains to be determined. *Likely, but not formally proven. Professional illustration by
Debra T. Dartez.
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malignancy, a process called graft-versus-leukemia (GVL) re-
sponse, but can also lead to detrimental graft-versus-host disease
(GVHD).109 There is ample evidence that both GVHD and GVL are
dependent on remaining host APC, of which DCs are the most
potent.15,110
GVL appears to occur at a lower threshold than GVHD in
studies of escalated donor lymphocyte infusions (DLI) in mice and
humans.109 In murine models, recipient DCs present in the spleen
or the LN are in contact with donor T cells and are sufficient to
prime robust GVL responses,111-113 whereas in the absence of
inflammation, peripheral tissues are not infiltrated by alloreactive
donor T cells,113 conferring a selective benefit in promoting GVL
without GVHD.111-113 This underpins the logic of delayed T-cell
add-back strategies and preemptive DLI, which allows the inflam-
matory insult of conditioning to subside before the infusion of
donor T cells.
The importance of recipient DCs in initiating GVHD has also
been clearly established. Recipient animals with defective APC
show attenuation of acute CD8 T cell–mediated GVHD114,115 and
recipient DC “add-back” is sufficient to induce GVHD.116 It is
possible host DC subsets that resist the transplantation conditioning
such as LCs and have a sufficiently long half-life could play a role
in the predilection of GVHD for certain target organs. Indeed,
cutaneous host DCs are sufficient to generate cutaneous GVHD on
DLI.117 In contrast to skin, other GVHD target organs have not yet
been closely scrutinized. The gut and associated Peyer patches may
harbor radio-resistant DC precursors, even though rapid turnover of
mesenteric LN DC is apparent.16 In the liver, the bulk of parenchy-
mal DCs rapidly equilibrate with the blood,117 but this does not
exclude a niche population of cycling DCs in focal GVHD targets
such as the portal triad of the liver.
The role of DCs in cutaneous GVHD in human allo-HCT is
starting to be unraveled. As in mice, human LCs and dermal DCs
survive conditioning therapy in significant numbers.17,118 A recent
study on a limited number of allo-HCT patients treated with
reduced intensity and nonmyeloablative regimen suggest that
recipient cutaneous DC survival is linked to the intensity of
conditioning and to GVHD.17,119 The correlations between cutane-
ous DC chimerism, GVHD kinetics, and risk of tumor relapse are
currently investigated in a more extensive study (M. Mielcarek,
M. Collin, and M.M., unpublished data, January 2009).
Future directions in research and possible
clinical implementation
Thirty-five years after their discovery, DCs have now emerged as
key modulators of immune processes, including antimicrobial
immunity, tumor immunity, autoimmunity, atherosclerosis, and
posttransplantation immune responses. These immune functions
are maintained by a heterogeneous population of DCs with
specialized functions. It is critical to understand the mechanisms
that regulate the homeostasis of DC subsets to better use their
therapeutic potential. This will require investigating the mecha-
nisms that regulate DC development, trafficking, localization, and
turnover in specialized niches in vivo, studies that will be possible
with currently evolving labeling and in vivo imaging technology.
Furthermore, selective targeting of DCs in vivo or ex vivo, for
example, via specific antibody or small molecules, may lead to
new immunomodulation strategies that will be beneficial for the
treatment of several human diseases. A main challenge for the fu-
ture is to translate what we have learned from the mouse into
humans and better explore the diversity of human lymphoid and
nonlymphoid organ DC populations. Toward this aim, improving
availability of human tissue samples and establishing more relevant
mouse models for the study of the human immune system will
be useful.120,121
Note added in proof. C. Auffray and F. Geissman, and K. Liu
and M. Nussenzweig, now demonstrate that MDP, in addition
to producing monocytes/macrophages and DCs, can also pro-
duce pDCs. Using adoptive transfer experiments, K. Liu and
M. Nussenzweig also found that MDP downstream development
branches into monocytes/macrophages and CDPs (Auffray et al125;
Liu et al126).
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